Abstract 651O
Background
EphrinB2 (B2) expressed in mUC is a gatekeeper blocking immune cell (IC) traffic. Blocking B2 with B4 facilitates IC traffic into the tumor and may be synergistic with PD1/PDL1 treatment (tx). This trial investigated the safety and efficacy of B4 + P in mUC.
Methods
Patients (pts) with mUC previously treated with platinum chemotherapy (PC) were eligible. Prior PD1/PDL1 was excluded. Tx consisted of P 200mg IV q3 weeks + B4 10mg/kg IV weekly in a 21 day cycle until progression (PD) or unacceptable toxicities (tox). Response was measured q6 weeks using RECIST 1.1. Primary endpoint was overall survival (OS), secondary endpoints were progression free survival (PFS) and duration of response (DOR), and objective response rate (ORR). Pts who did not complete 1 cycle of tx or did not get the first imaging were inevaluable for response. Tumor tissue for all evaluable pts were tested for B2 by Immunohistochemical (IHC) staining.
Results
69 pts enrolled between 12/2016 - 09/2020. Median age 67, male/female 58/11, prior lines of tx 1/1+ 63/6. Sites of disease at baseline: nodes 43 (62%), lungs 24 (35%), liver 16 (23%), bone 9 (13%). ECOG 0 39 (57%) vs. 1 30 (43%). Bellmunt risk groups 0/1/2-3 were 41/43/16%. 23% upper tract primary. Among all enrolled at a median follow up 25.4 mo (range 1.3-48.3), the median OS was 14.4 mo (95% CI 6.4, 21.4). The ORR was 38%, median PFS 4.0 mo (95% CI 2.3, 5.5) and median DOR 8.0 mo. Among 62 evaluable pts ORR was 42% (95% CI 30-55, 9 CR, 17 PR), 40 pts expressed B2 (65%). Among B2+ pts ORR was 57.5% (95% CI 42-74, 8CR, 15 PR), median OS 15.3 mo (95% CI 12.0- NE), PFS 6.5 mo (95% CI 26-12.8), DOR 27 mo (range 10.4, NE). Median cycles of tx 5 (range 1-36). 6 pts still on tx, 5 pts off tx without PD. 36 (52%) off tx due to PD, 4 tox 1 grade (G) 3 arthralgia, 1 G3 edema, 1 G3 abdominal pain and 1 G3 supraventricular tachycardia, 4 died on tx (1 organ failure attributed to P, 1 aspiration pneumonia, 2 decline in health status). Hypertension was the most common tox attributed to B4, 72% all G, 42 % G3-4. Other tox ≥10%: fatigue, anorexia, nausea, headache, proteinuria, hyperuricemia, rash, ↑AST, anemia.
Conclusions
B4 + P is well tolerated and may have synergistic efficacy in mUC. B2 was expressed in the majority of pts and predicted for improved tx outcome.
Clinical trial identification
NCT02717156.
Editorial acknowledgement
Legal entity responsible for the study
USC.
Funding
Merck and Vasgene.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Presenter: Thomas Powles
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
Presenter: Christian Pfister
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA27
Presenter: Srikala Sridhar
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Silke Gillessen
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast
Invited Discussant 651O and 652O
Presenter: Enrique Grande
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Silke Gillessen
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast